PATENT CLAIM ANALYSIS

Application Number: 15876960
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-09
Patent Classification: ["514", "252100"]

Abstract:
The present invention relates to compounds useful in the modulation of potassium channel activity in cells, in particular the activity of Kv1.3 channels found in T cells. The invention also relates to the use of these compounds in the treatment or prevention of autoimmune and inflammatory diseases, including multiple sclerosis, pharmaceutical compositions containing these compounds and methods for their preparation.

Claim (Index 114):
A method of treating a condition selected from autoimmune disorders, immune-mediated disorders, inflammatory disorders, or other disorders, or conditions which benefit clinically from immunosuppressants, including multiple sclerosis, type-1 diabetes mellitus, type-2 diabetes mellitus, rheumatoid arthritis, systemic lupus erythematosus, psoriasis, contact dermatitis, obesity, graft-versus host disease, transplant rejection, and delayed type hypersensitivity, including the step of administering an effective amount of a compound according to Formula (I): wherein G 1  denotes a single bond, G 2  denotes a CO group, X is selected from a single bond, an alkylene group having 1 to 6 carbon atoms optionally substituted with 1 or 2 substituents selected from fluoro or C 1 -C 6 -alkyl, Y is selected from an alkylene group having 1 to 6 carbon atoms optionally substituted one or two times with C 3 -C 8 -cycloalkyl or C 1 -C 3 -alkyl; or a 3-8-membered cycloalkylene group, Q is selected from O, NH or a single bond, W is selected from SO, SO 2  or a single bond, U is cycloalkyl, cycloalkenyl, heterocyclyl or heteroaryl, each of the above groups being optionally substituted with 1 to 3 substituents selected from Hal, NO 2 , CN, \u2014SO 2 \u2014C 1 -C 6 -alkyl, \u2014S\u2014C 1 -C 6 -alkyl, NMe 2 , C 1 -C 6 -alkyl, \u2014C(O)O\u2014C 1 -C 6 -alkyl, O\u2014C 1 -C 6 -alkyl, \u2014(CH 2 ) m \u2014O\u2014C 1 -C 6 -alkyl, \u2014C 1 -C 6 -halo-alkyl, or a 5-6-membered heteroaromatic group being optionally substituted by Hal, V is an aryl group optionally substituted with 1 to 3 substituents selected from Hal, NO 2 , CN, SO 2 \u2014C 1 -C 6  alkyl, NMe 2 , C 1 -C 6 -alkyl, O\u2014C 1 -C 6 -alkyl, \u2014(CH 2 ) m \u2014O\u2014C 1 -C 6 -alkyl, \u2014C 1 -C 6 -halo-alkyl, O\u2014C 1 -C 6 -halo-alkyl or a 5-6-membered heteroaromatic group, T denotes phenyl, triazolyl, thiazolyl, oxazolyl, oxadiazolyl, or pyrazolyl, R 1  is Hal, \u2014C 1 -C 6 -alkyl, O\u2014C 1 -C 6 -alkyl, \u2014(CH 2 ) m \u2014O\u2014C 1 -C 6 -alkyl, O\u2014C 1 -C 6 -halo-alkyl, \u2014(CH 2 ) m \u2014O\u2014C 1 -C 6 -halo-alkyl, \u2014SO 2 \u2014C 1 -C 6 -alkyl, \u2014(CH 2 ) m \u2014SO 2 \u2014C 1 -C 6 -alkyl, \u2014SO 2 \u2014C 1 -C 6 -halo-alkyl, \u2014(CH 2 ) m \u2014SO 2 \u2014C 1 -C 6 -halo-alkyl, \u2014SO 2 -3-8-cycloalkyl, \u2014(CH 2 ) m \u2014SO 2 -3-8-cycloalkyl, cyano or \u2014C 1 -C 6 -halo-alkyl, R 2  and R 2\u2032  are independently from one another H, Hal, \u2014C 1 -C 6 -alkyl, \u2014O\u2014C 1 -C 6 -alkyl, \u2014(CH 2 ) m \u2014O\u2014C 1 -C 6 -alkyl, O\u2014C 1 -C 6 -halo-alkyl, \u2014(CH 2 ) m \u2014O\u2014C 1 -C 6 -halo-alkyl, \u2014SO 2 \u2014C 1 -C 6 -alkyl, \u2014(CH 2 ) m \u2014SO 2 \u2014C 1 -C 6 -alkyl, \u2014SO 2 \u2014C 1 -C 6 -halo-alkyl, \u2014(CH 2 ) m \u2014SO 2 \u2014C 1 -C 6 -halo-alkyl, \u2014SO 2 -3-8-cycloalkyl, \u2014(CH 2 ) m \u2014SO 2 -3-8-cycloalkyl, \u2014C 1 -C 6 -halo-alkyl, or R 1  and R 2  are linked to form with the ring T to which they are attached a 7-12-membered fused heterocyclyl or 7-12-membered fused cycloalkyl, each of which may be optionally substituted with 1 to 3 Hal, \u2014C 1 -C 6 -halo-alkyl, NO 2 , CN, C 1 -C 6 -alkyl, \u2014(CH 2 ) m \u2014O\u2014C 1 -C 6 -alkyl, or \u2014O\u2014C 1 -C 6 -alkyl, R 3  is C 1 -C 6 -alkyl, C 1 -C 6 -haloalkyl, \u2014(CH 2 ) m \u2014O\u2014C 1 -C 6 -alkyl, or \u2014(CH 2 ) m \u2014O\u2014C 1 -C 6 -haloalkyl; a 3-8-membered cycloalkyl group, optionally substituted with 1 to 3 substituents independently selected from Hal, \u2014C 1 -C 6 -halo-alkyl, or C 1 -C 6 -alkyl; or a 3-8-membered heterocyclic group, optionally substituted with 1 to 3 substituents independently selected from Hal, \u2014C 1 -C 6 -halo-alkyl, NO 2 , CN, C 1 -C 6 -alkyl, \u2014(CH 2 ) m \u2014O\u2014C 1 -C 6 -alkyl, \u2014(CH 2 ) m \u2014SO 2 \u2014C 1 -C 6 -alkyl, \u2014SO 2 \u2014C 1 -C 6 -alkyl, \u2014O\u2014C 1 -C 6 -alkyl, \u2014(CH 2 ) m \u2014O\u2014C 1 -C 6 -halo-alkyl, \u2014(CH 2 ) m \u2014SO 2 \u2014C 1 -C 6 -halo-alkyl, \u2014SO 2 \u2014C 1 -C 6 -halo-alkyl, \u2014O\u2014C 1 -C 6 -halo-alkyl, \u2014C(O)\u2014C 1 -C 6 -alkyl, or \u2014C(O)O\u2014C 1 -C 6 -alkyl, R 4  denotes H, C 1 -C 6 -alkyl, or forms together with R 3  a 3-8-membered cycloalkyl ring, optionally substituted with Hal, \u2014C 1 -C 6 -halo-alkyl, NO 2 , CN, C 1 -C 6 -alkyl, \u2014(CH 2 ) m \u2014O\u2014C 1 -C 6 -alkyl, \u2014O\u2014C 1 -C 6 -alkyl, \u2014C(O)\u2014C 1 -C 6 -alkyl, or \u2014C(O)O\u2014C 1 -C 6 -alkyl, m is selected from 1, 2, 3 or 4, preferably 1 or 2, Hal is F, Cl, Br, or I, wherein -G 2 -Y\u2014W together is at least 3 atoms in length, or a pharmaceutically acceptable salts thereof, or an enantiomeric mixture of 2 enantiomers in all ratios, and/or as a mixture of diastereoisomers in all ratios.

Metadata:
- Claim Count in Document: 3.0
- Percentile: 86.0
- Lexical Diversity: 1.54762
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14118170', '15366513', '15026740', '13576798', '14322505']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7691150502750663
- 35 USC 102 Novelty (BERT): 0.5462447043480549
- Combined Prediction Score: 0.7468280156823651
- Mean Citation Score: 330.90194
- Max Citation Score: 387.18896
- Similarity Product: 235.3670544937896

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test